Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters - PubMed
. 2012 May;221(1):155-69.
doi: 10.1007/s00213-011-2555-2. Epub 2012 Jan 11.
Affiliations
- PMID: 22234378
- DOI: 10.1007/s00213-011-2555-2
Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters
Kieran J Davey et al. Psychopharmacology (Berl). 2012 May.
Abstract
Rationale: Atypical antipsychotic drugs (AAPDs) such as olanzapine have a serious side effect profile including weight gain and metabolic dysfunction, and a number of studies have suggested a role for gender in the susceptibility to these effects. In recent times, the gut microbiota has been recognised as a major contributor to the regulation of body weight and metabolism. Thus, we investigated the effects of olanzapine on body weight, behaviour, gut microbiota and inflammatory and metabolic markers in both male and female rats.
Methods: Male and female rats received olanzapine (2 or 4 mg/kg/day) or vehicle for 3 weeks. Body weight, food and water intake were monitored daily. The faecal microbial content was assessed by 454 pyrosequencing. Plasma cytokines (tumour necrosis alpha, interleukin 8 (IL-8), interleuin-6 and interleukin 1-beta (IL-1β)) as well as expression of genes including sterol-regulatory element binding protein-1c and CD68 were analysed.
Results: Olanzapine induced significant body weight gain in the female rats only. Only female rats treated with olanzapine (2 mg/kg) had elevated plasma levels of IL-8 and IL-1β, while both males and females had olanzapine-induced increases in adiposity and evidence of macrophage infiltration into adipose tissue. Furthermore, an altered microbiota profile was observed following olanzapine treatment in both genders.
Conclusions: This study furthers the theory that gender may impact on the nature of, and susceptibility to, certain side effects of antipsychotics. In addition, we demonstrate, what is to our knowledge the first time, an altered microbiota associated with chronic olanzapine treatment.
Similar articles
-
Davey KJ, Cotter PD, O'Sullivan O, Crispie F, Dinan TG, Cryan JF, O'Mahony SM. Davey KJ, et al. Transl Psychiatry. 2013 Oct 1;3(10):e309. doi: 10.1038/tp.2013.83. Transl Psychiatry. 2013. PMID: 24084940 Free PMC article.
-
Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, Vickers S, Cheetham S, Neill JC. Fell MJ, et al. Psychopharmacology (Berl). 2007 Oct;194(2):221-31. doi: 10.1007/s00213-007-0833-9. Epub 2007 Jun 21. Psychopharmacology (Berl). 2007. PMID: 17581744
-
Body weight and plasma levels of ghrelin and leptin during treatment with olanzapine.
Kim BJ, Sohn JW, Park CS, Hahn GH, Koo J, Noh YD, Lee CS. Kim BJ, et al. J Korean Med Sci. 2008 Aug;23(4):685-90. doi: 10.3346/jkms.2008.23.4.685. J Korean Med Sci. 2008. PMID: 18756058 Free PMC article.
-
Sentissi O, Epelbaum J, Olié JP, Poirier MF. Sentissi O, et al. Schizophr Bull. 2008 Nov;34(6):1189-99. doi: 10.1093/schbul/sbm141. Epub 2007 Dec 28. Schizophr Bull. 2008. PMID: 18165262 Free PMC article. Review.
-
Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin.
Jin H, Meyer JM, Mudaliar S, Jeste DV. Jin H, et al. Schizophr Res. 2008 Mar;100(1-3):70-85. doi: 10.1016/j.schres.2007.11.026. Epub 2008 Jan 18. Schizophr Res. 2008. PMID: 18206351 Free PMC article. Review.
Cited by
-
Zeb F, Osaili T, Obaid RS, Naja F, Radwan H, Cheikh Ismail L, Hasan H, Hashim M, Alam I, Sehar B, Faris ME. Zeb F, et al. Nutrients. 2023 Jan 4;15(2):259. doi: 10.3390/nu15020259. Nutrients. 2023. PMID: 36678130 Free PMC article. Review.
-
Niccolai E, Boem F, Russo E, Amedei A. Niccolai E, et al. Nutrients. 2019 Jan 12;11(1):156. doi: 10.3390/nu11010156. Nutrients. 2019. PMID: 30642052 Free PMC article. Review.
-
Mechanism and treatments of antipsychotic-induced weight gain.
Ye W, Xing J, Yu Z, Hu X, Zhao Y. Ye W, et al. Int J Obes (Lond). 2023 Jun;47(6):423-433. doi: 10.1038/s41366-023-01291-8. Epub 2023 Mar 23. Int J Obes (Lond). 2023. PMID: 36959286 Review.
-
Tsai YL, Liu YW, Wang PN, Lin CY, Lan TH. Tsai YL, et al. Front Psychiatry. 2022 Mar 15;13:836896. doi: 10.3389/fpsyt.2022.836896. eCollection 2022. Front Psychiatry. 2022. PMID: 35370854 Free PMC article.
-
Song X, Fan X, Li X, Zhang W, Gao J, Zhao J, Harrington A, Ziedonis D, Lv L. Song X, et al. Psychopharmacology (Berl). 2014 Jan;231(2):319-25. doi: 10.1007/s00213-013-3382-4. Epub 2013 Dec 14. Psychopharmacology (Berl). 2014. PMID: 24337064 Clinical Trial.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources